The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Mike Peters of The Alarm has appealed to people to become potential stem cell donors. Peters, who was forced to cancel a US ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world ...

More than 400 people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic Leukemia (B-ALL) next year in Spain, according to the latest projections from ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

recognize and attack cancer cells within the body—offer ... For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC ...

T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). T-ALL, known for its challenging ...